Geron Corporation

433 articles about Geron Corporation

• Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

  1/4/2023

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS) patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs).

• Geron Corporation Announces Proposed Public Offering of Common Stock - Jan 04, 2023

  1/4/2023

  Geron Corporation, a late-stage clinical biopharmaceutical company, announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering.

• Geron Announces Conference Call for Top-Line Results from IMerge Phase 3

  1/3/2023

  Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:00 a.m. ET.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 22, 2022

  12/22/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 867,130 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

  12/12/2022

  Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 17, 2022

  11/17/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 566,890 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Participate in Stifel 2022 Healthcare Conference

  11/7/2022

  Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET.

• Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

  11/3/2022

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10-13 in New Orleans, Louisiana.

• Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

  11/3/2022

  Geron Corporation today reported financial results for the third quarter of 2022 and upcoming expected milestones.

• Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

  10/27/2022

  Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 20, 2022

  10/20/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 843,260 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022

  9/22/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

  9/8/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company, announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022.

• Geron to Present at Upcoming September 2022 Investor Conferences

  9/1/2022

  Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City.

• Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

  8/22/2022

  Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 study evaluating imetelstat, a first-in-class telomerase inhibitor, in combination with ruxolitinib in patients with frontline myelofibrosis (MF).

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 18, 2022

  8/18/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Corporation Reports Second Quarter 2022 Financial Results

  8/11/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, reported financial results for the second quarter of 2022 and key upcoming expected milestones.

• Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

  8/4/2022

  Geron Corporation announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

  8/3/2022

  Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 22, 2022

  7/22/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 405,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.